Press Releases

IR Mobile SiteTear sheetEmail pagePDF viewPrint viewRSS FeedsEmail AlertSocial Media Sharing


Year:
Notify me when new press releases are posted to this site.
Press Releases
7/06/2009Cubist Pharmaceuticals Initiates Phase 2 Trial in Europe for Therapy to Reduce Blood Loss During Surgery in High Risk Patients
6/08/2009Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
6/05/2009INSERTING and REPLACING Cubist Pharmaceuticals to Present at June 2009 Investor Conferences
6/02/2009Cubist Pharmaceuticals to Present at June 2009 Investor Conferences
5/19/2009Cubist Pharmaceuticals Ranks No. 1 in The Boston Globe's Annual Globe 100 List of Best Performing Companies
4/29/2009Cubist Pharmaceuticals to Present at May 2009 Investor Conferences
4/21/2009Cubist Pharmaceuticals 1Q09 Total Net Revenues Up 37%; Total Net Revenues $121.1 Million; Net Product Revenues $114.6 Million
4/15/2009Cubist Pharmaceuticals to Announce Q109 Financial Results on Tuesday, April 21st, 2009
3/27/2009Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery
3/25/2009Cubist Pharmaceuticals to Present at Citi's 4th Annual Citi Biotech Day
3/23/2009Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc.
2/26/2009Cubist Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
2/17/2009Phase 1 Trial Begins for Investigational New Drug for MDR Gram-negative Infections
2/12/2009Cubist Pharmaceuticals Announces Start of First-in-Human Clinical Trial for Investigational New Drug for Clostridium difficile infections
2/10/2009Cubist Plans to Commence Patent Infringement Litigation against Teva Parenteral Medicines, Inc. In Response To ANDA filing
1/22/2009Cubist Pharmaceuticals Reports GAAP Diluted Net Income of $1.82 Per Share in Fourth Quarter 2008 and GAAP Diluted Net Income of $2.56 Per Share for Full Year 2008
1/12/2009Cubist Pharmaceuticals Announces Full Year 2008 Total Net Revenues of $433.6 Million
1/09/2009Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection
1/05/2009Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile
12/03/2008Cubist Pharmaceuticals to Present at RBC Capital Markets 2008 Healthcare Conference
 
 Source: SNL Financial LC 
Rows 141 through 160 of 408 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Copyright 2013, © SNL Financial LC  Terms of Use